NCT03277482 2025-05-31Durvalumab, Tremelimumab + Radiotherapy in Gynecologic CancerDana-Farber Cancer InstitutePhase 1 Terminated16 enrolled
NCT03452332 2023-09-13Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar CancersM.D. Anderson Cancer CenterPhase 1 Completed20 enrolled